TELA Bio Appoints Betty Jo Rocchio to Board, Announces Departure of Lisa Colleran

TELA Bio announces the appointment of Betty Jo Rocchio to its Board of Directors, bringing decades of experience in advancing clinical excellence, workforce innovation, and supply-chain transformation. Rocchio is a nationally recognized healthcare leader and one of Modern Healthcare’s 50 Most Influential Clinical Executives. Lisa Colleran, who has served on the Board for five years, has stepped down.

TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on innovative soft-tissue reconstruction solutions, has announced the appointment of Betty Jo Rocchio to its Board of Directors. Dr. Rocchio, a nationally recognized healthcare leader and one of Modern Healthcare’s 50 Most Influential Clinical Executives, brings decades of experience in advancing clinical excellence, workforce innovation, and supply-chain transformation TELA Bio Announces Addition of Betty Jo Rocchio to Board of Directors and the Departure of Director Lisa Colleran^[1].

Currently serving as Executive Vice President and Chief Nurse Executive at Advocate Health, Dr. Rocchio leads over 42,000 nurses and directs the enterprise-wide nursing strategy across a six-state system. She previously held leadership positions at Mercy and Mount Carmel Health System in Columbus, Ohio, and has earned a Doctor of Nursing Practice (DNP) in the Nurse Executive track from The Ohio State University TELA Bio Announces Addition of Betty Jo Rocchio to Board of Directors and the Departure of Director Lisa Colleran^[1].

The appointment of Dr. Rocchio follows the departure of Lisa Colleran, who has served on the Board for five years. Ms. Colleran, CEO of IC Surgical and former CEO of LifeCell Corporation, has provided extensive leadership and commercial expertise since joining the Board in 2020 TELA Bio Announces Addition of Betty Jo Rocchio to Board of Directors and the Departure of Director Lisa Colleran^[1].

"We are thrilled to welcome Betty Jo to our Board of Directors," said Antony Koblish, Co-founder and Chief Executive Officer of TELA Bio. "Her deep expertise in the group purchasing organization space and her proven ability to align clinical priorities with supply-chain strategy will be critical as we continue to drive value for our customers and shareholders" TELA Bio Announces Addition of Betty Jo Rocchio to Board of Directors and the Departure of Director Lisa Colleran^[1].

Dr. Rocchio expressed her enthusiasm for the opportunity to contribute to TELA Bio's mission. "Throughout my career, I’ve seen the critical role group purchasing organizations play in aligning clinical excellence with financial sustainability. TELA Bio is uniquely positioned to partner with providers and GPOs to deliver solutions that reduce costs while enhancing patient outcomes. I look forward to contributing to this important mission" TELA Bio Announces Addition of Betty Jo Rocchio to Board of Directors and the Departure of Director Lisa Colleran^[1].

TELA Bio also announced that Lisa Colleran has stepped down from the Board after five years of service. Ms. Colleran, CEO of IC Surgical and former CEO of LifeCell Corporation, has provided extensive leadership and commercial expertise since joining the Board in 2020 TELA Bio Announces Addition of Betty Jo Rocchio to Board of Directors and the Departure of Director Lisa Colleran^[1].

"On behalf of the Board and the entire TELA Bio team, I want to thank Lisa for her invaluable contributions over the past five years," said Mr. Koblish. "Her insights, perspective, and commitment have been instrumental as we advanced our strategy, expanded our portfolio, and grew our commercial footprint. We are grateful for her service and wish her continued success" TELA Bio Announces Addition of Betty Jo Rocchio to Board of Directors and the Departure of Director Lisa Colleran^[1].